480
Views
3
CrossRef citations to date
0
Altmetric
Author's View

β-catenin-mediated inhibition of cross-priming

A new mechanism for tumors to evade immunosurveillance

&
Article: e26920 | Received 21 Oct 2013, Accepted 22 Oct 2013, Published online: 06 Nov 2013

References

  • Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
  • Apetoh L, Locher C, Ghiringhelli F, Kroemer G, Zitvogel L. Harnessing dendritic cells in cancer. Semin Immunol 2011; 23:42 - 9; http://dx.doi.org/10.1016/j.smim.2011.01.003; PMID: 21295491
  • Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012; 61:223 - 30; http://dx.doi.org/10.1007/s00262-011-1138-8; PMID: 22065047
  • Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372 - 83; http://dx.doi.org/10.1016/j.immuni.2008.08.004; PMID: 18799145
  • Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 2012; 325:155 - 64; http://dx.doi.org/10.1016/j.canlet.2012.07.012; PMID: 22809568
  • Jiang A, Bloom O, Ono S, Cui W, Unternaehrer J, Jiang S, Whitney JA, Connolly J, Banchereau J, Mellman I. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007; 27:610 - 24; http://dx.doi.org/10.1016/j.immuni.2007.08.015; PMID: 17936032
  • Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC, Pulendran B. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010; 329:849 - 53; http://dx.doi.org/10.1126/science.1188510; PMID: 20705860
  • Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I, Jiang A. β-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8+ T cells. J Leukoc Biol 2013; http://dx.doi.org/10.1189/jlb.0613330; PMID: 24023259
  • Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121:1361 - 72; http://dx.doi.org/10.1172/JCI44325; PMID: 21436588
  • Hoogeboom D, Burgering BM. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta 2009; 1796:63 - 74; http://dx.doi.org/10.1016/j.bbcan.2009.02.002; PMID: 19268509